Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 3, 2026
Is Novo Nordisk (NYSE:NVO) Pricing Fair After A 43% One Year Share Price Decline?
View original at finance.yahoo.comIs Novo Nordisk (NYSE:NVO) Pricing Fair After A 43% One Year Share Price Decline? Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Novo Nordisk DCF analysis suggests the stock is undervalued by 65.2% with an intrinsic value of US$106.21 per share compared to recent share price of US$36.98
60% confidenceNovo Nordisk scores 5 out of 6 on Simply Wall St's valuation checks
60% confidenceThe DCF model shows the stock trades at a 65.2% discount to intrinsic estimate, indicating valuation materially below the model's fair value output
60% confidence
Data points we hold from this source
| Novo Nordisk A/S · free cash flow | 52100000000.0 DKK |
| Novo Nordisk A/S · year to date return | -29.4 percent |
| Novo Nordisk A/S · 30 day return | 0.9 percent |
| Novo Nordisk A/S · valuation score | 5 out_of_6 |
| Novo Nordisk A/S · 7 day return | 1.6 percent |
| Novo Nordisk A/S · projected free cash flow 2030 | 111.09 billion_DKK |
| Novo Nordisk A/S · discount to intrinsic value | 65.2 percent |
| Novo Nordisk A/S · 1 year return | -43.1 percent |
| Novo Nordisk A/S · intrinsic value dcf | 106.21 USD |